Recommended Pages at cardiovascularbusiness.com
CMS will reimburse for TAVR, with restrictions
cardiovascularbusiness.com — “The Center for Medicare & Medicaid Services (CMS) ruled May 1 that it would cover transcatheter aortic valve replacement (TAVR) under its Coverage with Evidence Development, but the agency included a series of conditions that must be met to receive reimbursement.” View full resource at cardiovascularbusiness.com
Most Recently Shared on May 3, 2012 at 2:33 pm By:
CardioBusiness Health Magazine
@CMSGov will reimburse for TAVR, with restrictions http://t.co/hsedK9rP #TAVR #reimbursement
AHA: Is ECMO the wave of the future?
cardiovascularbusiness.com — “NEWTON, Mass.—“Everyone who receives ECMO [extracorporeal membrane oxygenation] does not die,” said Joshua N. Baker, MD, a cardiovascular surgeon at Massachusetts General Hospital (MGH) in Boston, during a presentation April 26 at the American Heart Association's 22nd Annual Cardiovascular Nursing Conference. While ECMO is still sparsely used in the U.S., there may be ground for more widespread acceptance despite the costs, he told Cardiovascular Business.” View full resource at cardiovascularbusiness.com
Most Recently Shared on May 1, 2012 at 8:17 pm By:
CardioBusiness Health Magazine
@massgeneralnews @ryancdonovan Thanks for the RT #MGH CV surgeon Dr. Josh Baker talks about the success of ECMO http://t.co/1j4YcJcx
NEJM: Are drugs or lifestyle changes best for obese, diabetic youths?
cardiovascularbusiness.com — “Monotherapy with metformin was associated with durable glycemic control in approximately half of children and adolescents with type 2 diabetes; however, the addition of rosiglitazone, but not an intensive lifestyle intervention, was superior to metformin alone, according to the TODAY study published online April 29 in the New England Journal of Medicine. Yet, the editorialist questioned the study’s design.” View full resource at cardiovascularbusiness.com
Most Recently Shared on May 1, 2012 at 8:00 pm By:
CardioBusiness Health Magazine
@NEJM Are drugs or lifestyle changes best for obese, diabetic youths? http://t.co/kGP16N3m #type2 #obese #diabetes
AHA: Tired? It might be alarm fatigue
cardiovascularbusiness.com — “NEWTON, Mass.—Everyone has their professional trials. Is yours your device alarm system? As more devices infiltrate hospitals, many are becoming too sensitive and triggering false-positive alarms that plague staff, said Mary L. White, RN, MBA, senior risk manager at Brigham & Women’s Hospital in Boston, during an April 26 presentation at the 22nd Annual Conference on Cardiovascular Nursing sponsored by the American Heart Association (AHA).” View full resource at cardiovascularbusiness.com
Most Recently Shared on April 30, 2012 at 3:26 pm By:
CardioBusiness Health Magazine
Tired? Maybe it's alarm fatigue http://t.co/1kZCYzqs #alarm #beep #alarmfatigue
JAMA: Cardiac device infective endocarditis leads to infection, mortality
cardiovascularbusiness.com — “As patients age, the number requiring cardiac implantable electronic devices continues to grow. And while these devices are life-sustaining treatment options, they come with a hefty price tag and are prone to infection. Patients with cardiac device infective endocarditis have high rates of concomitant valve infection and mortality, according to a study published April 24 in the Journal of the American Medical Association.” View full resource at cardiovascularbusiness.com
Most Recently Shared on April 26, 2012 at 2:25 pm By:
CardioBusiness Health Magazine
Do devices carry risk of infection? Read the article here. http://t.co/CIxJf0Mb
Bos Sci now under fire for ICD-related patient death
cardiovascularbusiness.com — “With hundreds of thousands of devices on the market, malfunctions are always a possibility. This week, Boston Scientific’s Cognis and Teligen defibrillators are under fire after it was found that the transformer component could malfunction, which may have lead to a patient death.” View full resource at cardiovascularbusiness.com
Most Recently Shared on April 25, 2012 at 1:29 pm By:
CardioBusiness Health Magazine
Bos Sci under fire for ICD-related patient death http://t.co/w5PMw42K #implantabledevices #malfunction
Heart: Dabi cost-effective in U.K. analysis
cardiovascularbusiness.com — “Dabigatran, like other novel drugs, has upped the ante for the anticoagulant market due its ability to prevent stroke in atrial fibrillation (AF) patients without the need for continuous monitoring, like warfarin. However, while dabigatran has become a hit with some clinicians, many wonder whether the drug is cost-effective.” View full resource at cardiovascularbusiness.com
Most Recently Shared on April 24, 2012 at 4:15 pm By:
CardioBusiness Health Magazine
Dabigatran may be cost effective for U.K. population http://t.co/AT2hEWID #anticoagulants
JACC: Pelvic lead shielding reduces operator rad dose
cardiovascularbusiness.com — “The use of pelvic lead shielding during cardiac catheterization significantly reduces operator radiation dose, according to a study published in the April issue of the Journal of the American College of Cardiology: Cardiovascular Interventions. Operators who use pelvic lead shielding can perform four times as many femoral cases or twice as many radial cases with the same radiation exposure.” View full resource at cardiovascularbusiness.com
Most Recently Shared on April 24, 2012 at 3:29 pm By:
CardioBusiness Health Magazine
Pelvic lead shielding reduces operator rad dose http://t.co/8jy1pJJ7 #radiationsafety
Circ: PCI quality measures need more scrutiny
cardiovascularbusiness.com — “What good are quality metrics if they measure factors that hospitals can’t change? Using readmission data after PCI in hospitals in Massachusetts, researchers attempted to identify modifiable deficiencies that hospitals could target to improve performance. What they found was a wide variation in 30-day all-cause risk-standardized readmission rates, little of which was attributable to differences in procedural and postprocedural factors.” View full resource at cardiovascularbusiness.com
Most Recently Shared on April 23, 2012 at 2:45 pm By:
CardioBusiness Health Magazine
PCI quality measures need more scrutiny http://t.co/cjTo0SpX #PCI #coronaryintervention
AJMC: Simplifying dosing regimens may improve medication adherence
cardiovascularbusiness.com — “A once-daily dosing regimen was related to greater adherence versus a twice-daily regimen with prescription medications used by patients with cardiovascular disease, according to a large analysis in the March issue of the American Journal of Managed Care.” View full resource at cardiovascularbusiness.com
Most Recently Shared on April 17, 2012 at 3:20 pm By:
CardioBusiness Health Magazine
AJMC: Simplifying dosing regimens may improve medication adherence http://t.co/abV97lYE #adherence #doseofgoodnews
Circ: Safety data give biodegradable coronary stents boost
cardiovascularbusiness.com — “A fully biodegradable coronary artery stent appeared to be safe at 10 years, according to a single-center study published April 16 in Circulation. The authors said their findings will facilitate entry of biodegradable coronary stents in interventional cardiology.” View full resource at cardiovascularbusiness.com
Most Recently Shared on April 17, 2012 at 2:48 pm By:
CardioBusiness Health Magazine
Circ: Safety data give biodegradable coronary stents boost http://t.co/fz72qFoy #drugelutingstents
JACC: As DES mature, do sex differences still exist?
cardiovascularbusiness.com — “The unrestricted use of drug-eluting stents (DES) is associated with similar long-term safety and efficacy among women and men with coronary artery disease, according to a study in the March issue of the Journal of the American College of Cardiology: Cardiovascular Interventions. However, the accompanying editorialists wrote that “we are only at our infancy in our understanding of sex differences in cardiovascular disease.”” View full resource at cardiovascularbusiness.com
Most Recently Shared on April 16, 2012 at 5:50 pm By:
CardioBusiness Health Magazine
JACC: As DES mature, do sex differences still exist? http://t.co/FO2jMZJS #battleofthesexes
ACC: Cost-benefit of remote monitoring depends on players
cardiovascularbusiness.com — “CHICAGO—Calculating the cost-benefit ratio of remote monitoring patients who have implantable cardioverter-defibrillators depends on many variables, and the answer hinges on who pays and who benefits, said Mark H. Schoenfeld, MD, of Yale University School of Medicine in New Haven, Conn., in a March 24 presentation at the 61st annual American College of Cardiology (ACC) scientific session.” View full resource at cardiovascularbusiness.com
Most Recently Shared on March 29, 2012 at 4:30 pm By:
CardioBusiness Health Magazine
@YaleMed What's the cost-benefit ratio of remote monitoring? http://t.co/TBiw1KYU #ACC12 #telehealth
Cardiovascular Business ACC: Docs discuss beef with healthcare reform bill
cardiovascularbusiness.com — “CHICAGO—The Patient Protection and Affordable Care Act has been debated and discussed at nauseaum, but how will the guts of the bill actually impact doctors? This is the question Richard E. Anderson, MD, chairman and CEO of The Doctors Company, asked March 25 at an afternoon session at the 61st annual American College of Cardiology (ACC) Scientific Session. While the bill’s goal is to insure more Americans, Anderson said ultimately it will increase demand yet offer no break in terms of supply or” View full resource at cardiovascularbusiness.com
Most Recently Shared on March 28, 2012 at 3:00 pm By:
CardioBusiness Health Magazine
What will become of healthcare reform? Docs discuss beef at #ACC12 http://t.co/5ft33yBb Check out the round-for-round fight...
ACC: CCTA can improve chest pain diagnoses without increased costs
cardiovascularbusiness.com — “CHICAGO—Using cardiac CT angiography (CCTA) early on in the presentation of chest pain may more accurately assess patients who should be admitted for MI, according to the results of the late-breaking ROMICAT II trial presented March 27 at the 61st annual American College of Cardiology (ACC) scientific session. Additionally, CCTA resulted in a reduction of length of stay at essentially no increased cost.” View full resource at cardiovascularbusiness.com
Most Recently Shared on March 28, 2012 at 2:25 pm By:
CardioBusiness Health Magazine
#ROMICAT II trial shows #CCTA can help improve chest pain diagnoses http://t.co/tWMEWf8p #withoutincreasedcost
